ReviewCureus2025
Efficacy and Safety of Percutaneous Kyphoplasty Combined With Zoledronic Acid for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic vertebral compression fractures (OVCFs) are a significant source of pain and disability among the elderly. While percutaneous kyphoplasty (PKP) offers mechanical stabilization and pain relief, it does not address the underlying bone fragility. Zoledronic acid (ZOL), a strong bisphosphonate, makes bones stronger and may stop them from breaking again. This meta-analysis assessed the efficacy and safety of combining PKP with ZOL versus PKP alone in patients with OVCFs. A systematic search of PubMed, Cochrane Library, and Clinicaltrials.gov was performed up to August 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Randomized controlled trials (RCTs) comparing PKP plus ZOL versus PKP alone were included. Data were pooled using Review Manager (RevMan) version 5.4 (The Cochrane Collaboration, London, England, UK). Mean difference (MD) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Five RCTs involving 997 patients (499 PKP + ZOL; 498 PKP) were analyzed. The combination therapy showed greater pain reduction (visual analog scale (VAS): MD = -1.18 (-2.04, -0.31)), improved function (Oswestry Disability Index (ODI): MD = -9.18 (-21.57, 3.20)), and increased Cobb angle correction (MD = 1.88 (0.14, 3.63)). Bone mineral density (BMD) improved significantly (MD = 0.08 (0.06, 0.11)), while bone turnover markers (procollagen type I N-terminal propeptide (PINP), β-C-terminal telopeptide (β-CTX), and N-terminal mid-fragment of osteocalcin (N-MID osteocalcin)) were markedly reduced. Adverse events were more common with ZOL (RR = 5.46 (3.75, 7.96)) but were mild and transient. In OVCF patients, combining PKP with ZOL gives better clinical, functional, and bone-strengthening advantages than PKP alone. Even while small side effects happen more often, the treatment is still safe and well-tolerated. This combined method works well to fix both the mechanical stability and the metabolic fragility of osteoporotic fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.